Hypertension Diagnostics Performance
| HDIIDelisted Stock | USD 0 0.0008 38.10% |
The company retains a Market Volatility (i.e., Beta) of 5.1, which attests to a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Hypertension Diagnostics will likely underperform. Hypertension Diagnostics right now retains a risk of 0.0%. Please check out Hypertension Diagnostics treynor ratio, kurtosis, period momentum indicator, as well as the relationship between the downside variance and day median price , to decide if Hypertension Diagnostics will be following its current trending patterns.
Risk-Adjusted Performance
0 of 100
Weak | Strong |
Very Weak
Over the last 90 days Hypertension Diagnostics has generated negative risk-adjusted returns adding no value to investors with long positions. Despite fairly strong forward indicators, Hypertension Diagnostics is not utilizing all of its potentials. The recent stock price confusion, may contribute to short-horizon losses for the traders. ...more
| Begin Period Cash Flow | 285.4 K | |
| Total Cashflows From Investing Activities | -2111.00 |
Hypertension |
Hypertension Diagnostics Relative Risk vs. Return Landscape
If you would invest 0.29 in Hypertension Diagnostics on August 30, 2024 and sell it today you would earn a total of 0.00 from holding Hypertension Diagnostics or generate 0.0% return on investment over 90 days. Hypertension Diagnostics is currently does not generate positive expected returns and assumes 0.0% risk (volatility on return distribution) over the 90 days horizon. In different words, 0% of pink sheets are less volatile than Hypertension, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Hypertension Diagnostics Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Hypertension Diagnostics' investment risk. Standard deviation is the most common way to measure market volatility of pink sheets, such as Hypertension Diagnostics, and traders can use it to determine the average amount a Hypertension Diagnostics' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.0
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| HDII |
Based on monthly moving average Hypertension Diagnostics is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Hypertension Diagnostics by adding Hypertension Diagnostics to a well-diversified portfolio.
Hypertension Diagnostics Fundamentals Growth
Hypertension Pink Sheet prices reflect investors' perceptions of the future prospects and financial health of Hypertension Diagnostics, and Hypertension Diagnostics fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Hypertension Pink Sheet performance.
| Return On Asset | 3.0E-4 | ||||
| Profit Margin | (0.03) % | ||||
| Operating Margin | 0.0002 % | ||||
| Current Valuation | 5.26 M | ||||
| Shares Outstanding | 52.39 M | ||||
| Price To Earning | (0.03) X | ||||
| Price To Sales | 0.15 X | ||||
| Revenue | 3.79 M | ||||
| EBITDA | 72.29 K | ||||
| Cash And Equivalents | 5.66 K | ||||
| Total Debt | 4.69 M | ||||
| Book Value Per Share | (0.09) X | ||||
| Cash Flow From Operations | (389.28 K) | ||||
| Earnings Per Share | (0) X | ||||
| Total Asset | 1.28 M | ||||
| Retained Earnings | (30.68 M) | ||||
| Current Asset | 277 K | ||||
| Current Liabilities | 1.13 M | ||||
About Hypertension Diagnostics Performance
By evaluating Hypertension Diagnostics' fundamental ratios, stakeholders can gain valuable insights into Hypertension Diagnostics' financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if Hypertension Diagnostics has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Hypertension Diagnostics has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements. Please also refer to our technical analysis and fundamental analysis pages.
Hypertension Diagnostics, Inc. designs, develops, manufactures, and markets proprietary noninvasive medical devices that detect subtle changes in the elasticity of arteries in the United States and internationally. Hypertension Diagnostics, Inc. was founded in 1988 and is based in Richmond Hill, Canada. Hypertension Diag operates under Shell Companies classification in the United States and is traded on OTC Exchange.Things to note about Hypertension Diagnostics performance evaluation
Checking the ongoing alerts about Hypertension Diagnostics for important developments is a great way to find new opportunities for your next move. Pink Sheet alerts and notifications screener for Hypertension Diagnostics help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Hypertension Diagnostics is not yet fully synchronised with the market data | |
| Hypertension Diagnostics has some characteristics of a very speculative penny stock | |
| Hypertension Diagnostics has a very high chance of going through financial distress in the upcoming years | |
| Hypertension Diagnostics currently holds 4.69 M in liabilities. Hypertension Diagnostics has a current ratio of 0.51, indicating that it has a negative working capital and may not be able to pay financial obligations when due. Debt can assist Hypertension Diagnostics until it has trouble settling it off, either with new capital or with free cash flow. So, Hypertension Diagnostics' shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Hypertension Diagnostics sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Hypertension to invest in growth at high rates of return. When we think about Hypertension Diagnostics' use of debt, we should always consider it together with cash and equity. | |
| The entity reported the previous year's revenue of 3.79 M. Net Loss for the year was (125.39 K) with profit before overhead, payroll, taxes, and interest of 954.47 K. | |
| Hypertension Diagnostics currently holds about 5.66 K in cash with (389.28 K) of positive cash flow from operations. |
- Analyzing Hypertension Diagnostics' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Hypertension Diagnostics' stock is overvalued or undervalued compared to its peers.
- Examining Hypertension Diagnostics' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Hypertension Diagnostics' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Hypertension Diagnostics' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Hypertension Diagnostics' pink sheet. These opinions can provide insight into Hypertension Diagnostics' potential for growth and whether the stock is currently undervalued or overvalued.
Check out Risk vs Return Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in gross domestic product. You can also try the Premium Stories module to follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope.
Other Consideration for investing in Hypertension Pink Sheet
If you are still planning to invest in Hypertension Diagnostics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Hypertension Diagnostics' history and understand the potential risks before investing.
| Idea Analyzer Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas | |
| Bond Analysis Evaluate and analyze corporate bonds as a potential investment for your portfolios. | |
| ETF Categories List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments | |
| Price Ceiling Movement Calculate and plot Price Ceiling Movement for different equity instruments | |
| Financial Widgets Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets | |
| Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets | |
| Bonds Directory Find actively traded corporate debentures issued by US companies |